Fierce Pharma
Fierce Biotech
Fierce Healthcare
Fierce Life Sciences Events
Advertise
About Us
Biotech
Cell & Gene Therapy
Clinical Data
Venture Capital
Deals
Research
Medtech
Devices
Diagnostics
AI and Machine Learning
CRO
Special Reports
Trending
Biologics
Clinical Development
Ophthalmology
Cell & Gene Therapy
Fierce 50
Special Report
Awards Gala
Awards
CRO Awards
Innovation Awards
Resources
Fierce Events
Industry Events
Webinars
Podcasts
Whitepapers
Survey
Events
Subscribe
Subscribe
Biotech
Cell & Gene Therapy
Clinical Data
Venture Capital
Deals
Research
Medtech
Devices
Diagnostics
AI and Machine Learning
CRO
Special Reports
Trending
Biologics
Clinical Development
Ophthalmology
Cell & Gene Therapy
Fierce 50
Special Report
Awards Gala
Awards
CRO Awards
Innovation Awards
Resources
Fierce Events
Industry Events
Webinars
Podcasts
Whitepapers
Survey
Events
Subscribe
Fierce Pharma
Fierce Biotech
Fierce Healthcare
Fierce Life Sciences Events
Advertise
About Us
Astellas Pharma
Biotech
Aviceda eye disease hopeful fails to top Astellas med in phase 2
Aviceda was also testing the nanoparticle in diabetic macular edema, but halted the study early due to insufficient supply and funding constraints.
Darren Incorvaia
Dec 15, 2025 2:14pm
GSK chief steps down in stunning move—Chutes & Ladders
Oct 3, 2025 8:30am
Astellas offers lab space to help Japanese biotechs 'go global'
Jun 13, 2025 4:41am
Astellas stops development of early-stage lymphoma CAR-T
Jan 9, 2025 6:49am
Astellas pays Sangamo $20M to boost neurological gene therapies
Dec 19, 2024 7:13am
Astellas telegraphs new cell therapy site in Japan, 24 US layoffs
Oct 9, 2024 5:45pm
